The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today

ebola virus

Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon

February 10, 2020 - 16:22 -- Open Access
Author(s): 
Jessica L. Abbate, Pierre Becquart, Eric Leroy, Vanessa O. Ezenwa, Benjamin Roche
Reference: 
Emerging Infectious Diseases, Volume 26, Volume 26, Number 2—February 2020

An association between malaria and risk for death among patients with Ebola virus disease has suggested within-host interactions between Plasmodium falciparum parasites and Ebola virus. To determine whether such an interaction might also influence the probability of acquiring either infection, we used a large snapshot surveillance study from rural Gabon to test if past exposure to Ebola virus is associated with current infection with Plasmodium spp. during nonepidemic conditions.

In Vivo Activity of Amodiaquine against Ebola Virus Infection

January 15, 2020 - 07:58 -- Open Access
Author(s): 
DeWald LE, Johnson JC, Gerhardt DM, Torzewski LM, Postnikova E, Honko AN, Janosko K, Huzella L, Dowling WE, Eakin AE, Osborn BL, Gahagen J, Tang L, Green CE, Mirsalis JC, Holbrook MR, Jahrling PB, Dyall J, Hensley LE
Reference: 
Scientific Reports, 2019 Dec 27; 9(1):20199

During the Ebola virus disease (EVD) epidemic in Western Africa (2013‒2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine.

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection

November 30, 2019 - 20:12 -- Open Access
Author(s): 
Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S
Reference: 
PLoS Negl Trop Dis. 2019 Nov 21;13(11):e0007890.

Recent outbreaks of the Ebola virus (EBOV) have focused attention on the dire need for antivirals to treat these patients. We identified pyronaridine tetraphosphate as a potential candidate as it is an approved drug in the European Union which is currently used in combination with artesunate as a treatment for malaria (EC50 between 420 nM-1.14 μM against EBOV in HeLa cells).

Subscribe to RSS - ebola virus